Patient-performed extraction of faecal calprotectin
Authors:
- Vendel KristensenVKVendel Kristensen
- Trine LauritzenTLTrine Lauritzen
- Lars-Petter Jelsness-JørgensenLJLars-Petter Jelsness-Jørgensen
- Svein Oskar FrigstadSFSvein Oskar Frigstad
- Christian CorwinCCChristian Corwin
- Bjørn MoumBMBjørn Moum
- 1 January 2016
- journal article
- research article
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 54 (8)
Abstract
Background: Faecal (f-) calprotectin is a widely used marker for intestinal inflammation. However, extraction procedure is time consuming and cumbersome. The main aim of this study was to evaluate patient-performed extraction of f-calprotectin compared to extraction performed in the laboratory.Methods: A total of 81 adult patients with an established diagnosis of inflammatory bowel disease provided two samples from the same bowel movement, one conventional faeces sample and one sample with a patient administered extraction device. A laboratory technician extracted the conventional faeces sample with the same extraction device.Results: F-calprotectin results from the laboratory-performed extraction and the patient-performed extraction correlated significantly, with a Spearman rank correlation coefficient of 0.92. Method comparison showed a slope of 1.20 (95% confidence interval 1.08–1.36) with intercept of –0.30 (95% confidence interval –9.00 to 4.62). This demonstrates a small proportional difference between the results from the home extracted samples and the results from the laboratory extracted samples, where the home extracted samples are slightly higher. However, six of the 81 patients had made obvious mistakes in the extraction process and their samples were excluded from the study.Conclusions: Patient administered extraction of f-calprotectin can be a realistic alternative for selected patients. However, instructions must be very precise to avoid mistakes.Keywords
This publication has 26 references indexed in Scilit:
- Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's diseaseScandinavian Journal of Gastroenterology, 2012
- Correlation Between the Crohn's Disease Activity and Harvey–Bradshaw Indices in Assessing Crohn's Disease SeverityClinical Gastroenterology and Hepatology, 2010
- Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel diseaseWorld Journal of Gastroenterology, 2008
- Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?Gut, 2007
- A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative ColitisGastroenterology, 2007
- The Montreal classification of inflammatory bowel disease: controversies, consensus, and implicationsGut, 2006
- Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s diseaseGut, 2005
- Diagnostic value of faecal calprotectin in paediatric gastroenterology clinical practiceDigestive and Liver Disease, 2004
- Correlation between Faecal Excretion of Indium-111-Labelled Granulocytes and Calprotectin, a Granulocyte Marker Protein, in Patients with Inflammatory Bowel DiseaseScandinavian Journal of Gastroenterology, 1999
- Assessment of Disease Activity in Ulcerative Colitis by Faecal Calprotectin, a Novel Granulocyte Marker ProteinDigestion, 1997